Analyze the actual therapeutic effect of cabotegravir/rilpivirine injection suspension

Cabotegravir/rilpivirine injection suspension (cabotegravir and rilpivirine) , as an innovative long-acting injection regimen, is specially designed for adultsHIV infected patients. The drug is a combination of cabotegravir (HIV-1integrase strand transfer inhibitor) and rilpivirine (HIV-1non-nucleoside reverse transcriptase inhibitor), providing a comprehensive treatment option for HIV-1 viral infection.

In clinical practice, the therapeutic effect of cabotegravir/rilpivirine injection suspension has attracted much attention. Two phase 3 randomized, multicenter, active-controlled, parallel-arm, open-label, non-inferiority clinical trials - FLAIR and ATLAS - provided insight into its efficacy. The two trials included a total of 1,245 subjects who had achieved virological suppression, providing a solid basis for evaluating drug effects.

In the FLAIR trial, at 48 weeks, the cabotegravir / rilpivirine group was as effective as the control group, with only 2%of subjectsHIV-1 RNAlevels rebounded to above 50copies/mL. Results from the extended trial were equally encouraging, with the proportion of subjects with rebound plasma HIV-1 RNA levels remaining low regardless of whether there was an oral run-in period. In the ATLAS trial, the therapeutic effect of the cabotegravir / rilpivirine group was also comparable to that of the control group, further verifying its stable and reliable antiviral effect.

In addition, a comparison of the monthly dosing schedule with the every2monthly dosing schedule also demonstrated the flexibility of cabotegravir/rilpivirine injectable suspension. At week 48, the proportion of subjects whose HIV-1 RNA levels rebounded under both dosage regimens was very low, and the difference was not significant, providing patients with more diversified treatment options.

Of course, any drug may cause certain side effects. cabotewe/Rilpivirine injection suspension is no exception. Common side effects include pain, tenderness, and hard lumps at the injection site, as well as systemic symptoms such as fever, fatigue, and headache. For serious side effects, such as allergies, difficulty breathing, etc., patients should seek medical advice promptly and seek professional medical advice.

Overall, cabotegravir/rilpivirine injection suspension has shown significant antiviral effects in actual treatment, providing a new and effective treatment option for adults with HIV infection. Its long-acting injection solution not only improves the convenience of treatment, but also brings patients a better treatment experience and quality of life. In future clinical practice, cabotegravir/rilpivirine injection suspension is expected to become one of the important drugs in the field of HIV treatment.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf